Optimizing RBC Transfusion Outcomes in Patients with Acute Illness and in the Chronic Transfusion Setting

IF 2.5 2区 医学 Q2 HEMATOLOGY
Ross M. Fasano , Allan Doctor , Sean R. Stowell , Philip C. Spinella , Jeffrey L. Carson , Cheryl L. Maier , Cassandra D. Josephson , Darrell J. Triulzi
{"title":"Optimizing RBC Transfusion Outcomes in Patients with Acute Illness and in the Chronic Transfusion Setting","authors":"Ross M. Fasano ,&nbsp;Allan Doctor ,&nbsp;Sean R. Stowell ,&nbsp;Philip C. Spinella ,&nbsp;Jeffrey L. Carson ,&nbsp;Cheryl L. Maier ,&nbsp;Cassandra D. Josephson ,&nbsp;Darrell J. Triulzi","doi":"10.1016/j.tmrv.2023.150758","DOIUrl":null,"url":null,"abstract":"<div><p>Red blood cell (RBC) transfusion is a common clinical intervention used to treat patients with acute and chronic anemia. The decision to transfuse RBCs in the acute setting is based on several factors but current clinical studies informing optimal RBC transfusion decision making (TDM) are largely based upon hemoglobin (Hb) level. In contrast to transfusion in acute settings, chronic RBC transfusion therapy has several different purposes and is associated with distinct transfusion risks such as iron overload and RBC alloimmunization. Consequently, RBC TDM in the chronic setting requires optimizing the survival of transfused RBCs in order to reduce transfusion exposure over the lifespan of an individual and the associated transfusion complications mentioned. This review summarizes the current medical literature addressing optimal RBC-TDM in the acute and chronic transfusion settings and discusses the current gaps in knowledge which need to be prioritized in future national and international research initiatives.</p></div>","PeriodicalId":56081,"journal":{"name":"Transfusion Medicine Reviews","volume":"37 4","pages":"Article 150758"},"PeriodicalIF":2.5000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transfusion Medicine Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0887796323000482","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Red blood cell (RBC) transfusion is a common clinical intervention used to treat patients with acute and chronic anemia. The decision to transfuse RBCs in the acute setting is based on several factors but current clinical studies informing optimal RBC transfusion decision making (TDM) are largely based upon hemoglobin (Hb) level. In contrast to transfusion in acute settings, chronic RBC transfusion therapy has several different purposes and is associated with distinct transfusion risks such as iron overload and RBC alloimmunization. Consequently, RBC TDM in the chronic setting requires optimizing the survival of transfused RBCs in order to reduce transfusion exposure over the lifespan of an individual and the associated transfusion complications mentioned. This review summarizes the current medical literature addressing optimal RBC-TDM in the acute and chronic transfusion settings and discusses the current gaps in knowledge which need to be prioritized in future national and international research initiatives.

优化急性疾病患者和慢性输血环境中的红细胞输血结果。
红细胞输注是一种常见的临床干预措施,用于治疗急慢性贫血患者。在急性情况下输注红细胞的决定基于几个因素,但目前的临床研究表明,最佳红细胞输注决策(TDM)主要基于血红蛋白(Hb)水平。与急性情况下的输血相比,慢性红细胞输血治疗有几个不同的目的,并与不同的输血风险有关,如铁过载和红细胞同种免疫。因此,慢性环境中的红细胞TDM需要优化输血的红细胞的存活率,以减少个体寿命内的输血暴露和相关的输血并发症。这篇综述总结了当前关于急性和慢性输血环境中最佳RBC-TDM的医学文献,并讨论了当前需要在未来国家和国际研究计划中优先考虑的知识差距。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Transfusion Medicine Reviews
Transfusion Medicine Reviews 医学-血液学
CiteScore
11.60
自引率
0.00%
发文量
40
审稿时长
21 days
期刊介绍: Transfusion Medicine Reviews provides an international forum in English for the publication of scholarly work devoted to the various sub-disciplines that comprise Transfusion Medicine including hemostasis and thrombosis and cellular therapies. The scope of the journal encompasses basic science, practical aspects, laboratory developments, clinical indications, and adverse effects.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信